158 related articles for article (PubMed ID: 20041717)
1. Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues.
Pasco MY; Rotili D; Altucci L; Farina F; Rouleau GA; Mai A; Néri C
J Med Chem; 2010 Feb; 53(3):1407-11. PubMed ID: 20041717
[TBL] [Abstract][Full Text] [Related]
2. Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1.
Catoire H; Pasco MY; Abu-Baker A; Holbert S; Tourette C; Brais B; Rouleau GA; Parker JA; Néri C
Hum Mol Genet; 2008 Jul; 17(14):2108-17. PubMed ID: 18397876
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.
Abu-Baker A; Laganiere S; Fan X; Laganiere J; Brais B; Rouleau GA
Traffic; 2005 Sep; 6(9):766-79. PubMed ID: 16101680
[TBL] [Abstract][Full Text] [Related]
4. Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells.
Wang Q; Mosser DD; Bag J
Hum Mol Genet; 2005 Dec; 14(23):3673-84. PubMed ID: 16239242
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk between canonical Wnt signaling and the sirtuin-FoxO longevity pathway to protect against muscular pathology induced by mutant PABPN1 expression in C. elegans.
Pasco MY; Catoire H; Parker JA; Brais B; Rouleau GA; Néri C
Neurobiol Dis; 2010 Jun; 38(3):425-33. PubMed ID: 20227501
[TBL] [Abstract][Full Text] [Related]
6. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.
Corbeil-Girard LP; Klein AF; Sasseville AM; Lavoie H; Dicaire MJ; Saint-Denis A; Pagé M; Duranceau A; Codère F; Bouchard JP; Karpati G; Rouleau GA; Massie B; Langelier Y; Brais B
Neurobiol Dis; 2005 Apr; 18(3):551-67. PubMed ID: 15755682
[TBL] [Abstract][Full Text] [Related]
7. Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy.
Davies JE; Rose C; Sarkar S; Rubinsztein DC
Sci Transl Med; 2010 Jun; 2(34):34ra40. PubMed ID: 20519718
[TBL] [Abstract][Full Text] [Related]
8. The dynamism of PABPN1 nuclear inclusions during the cell cycle.
Marie-Josée Sasseville A; Caron AW; Bourget L; Klein AF; Dicaire MJ; Rouleau GA; Massie B; Langelier Y; Brais B
Neurobiol Dis; 2006 Sep; 23(3):621-9. PubMed ID: 16860991
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy.
Doki T; Yamashita S; Wei FY; Hara K; Yamamoto T; Zhang Z; Zhang X; Tawara N; Hino H; Uyama E; Kurashige T; Maruyama H; Tomizawa K; Ando Y
Lab Invest; 2019 Nov; 99(11):1728-1740. PubMed ID: 30894671
[TBL] [Abstract][Full Text] [Related]
10. Nuclear speckles are involved in nuclear aggregation of PABPN1 and in the pathophysiology of oculopharyngeal muscular dystrophy.
Bengoechea R; Tapia O; Casafont I; Berciano J; Lafarga M; Berciano MT
Neurobiol Dis; 2012 Apr; 46(1):118-29. PubMed ID: 22249111
[TBL] [Abstract][Full Text] [Related]
11. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.
Ota H; Tokunaga E; Chang K; Hikasa M; Iijima K; Eto M; Kozaki K; Akishita M; Ouchi Y; Kaneki M
Oncogene; 2006 Jan; 25(2):176-85. PubMed ID: 16170353
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors.
Mai A; Massa S; Lavu S; Pezzi R; Simeoni S; Ragno R; Mariotti FR; Chiani F; Camilloni G; Sinclair DA
J Med Chem; 2005 Dec; 48(24):7789-95. PubMed ID: 16302818
[TBL] [Abstract][Full Text] [Related]
13. Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy.
Messaed C; Dion PA; Abu-Baker A; Rochefort D; Laganiere J; Brais B; Rouleau GA
Neurobiol Dis; 2007 Jun; 26(3):546-57. PubMed ID: 17418585
[TBL] [Abstract][Full Text] [Related]
14. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.
Chartier A; Benoit B; Simonelig M
EMBO J; 2006 May; 25(10):2253-62. PubMed ID: 16642034
[TBL] [Abstract][Full Text] [Related]
15. A de novo PABPN1 germline mutation in a patient with oculopharyngeal muscular dystrophy.
Gürtler N; Plasilova M; Podvinec M; Boesch N; Müller H; Heinimann K
Laryngoscope; 2006 Jan; 116(1):111-4. PubMed ID: 16481821
[TBL] [Abstract][Full Text] [Related]
16. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice.
Davies JE; Wang L; Garcia-Oroz L; Cook LJ; Vacher C; O'Donovan DG; Rubinsztein DC
Nat Med; 2005 Jun; 11(6):672-7. PubMed ID: 15864313
[TBL] [Abstract][Full Text] [Related]
17. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy.
Davies JE; Sarkar S; Rubinsztein DC
Hum Mol Genet; 2006 Jan; 15(1):23-31. PubMed ID: 16311254
[TBL] [Abstract][Full Text] [Related]
18. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody.
Verheesen P; de Kluijver A; van Koningsbruggen S; de Brij M; de Haard HJ; van Ommen GJ; van der Maarel SM; Verrips CT
Hum Mol Genet; 2006 Jan; 15(1):105-11. PubMed ID: 16319127
[TBL] [Abstract][Full Text] [Related]
19. Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder.
Davies JE; Berger Z; Rubinsztein DC
Int J Biochem Cell Biol; 2006; 38(9):1457-62. PubMed ID: 16530457
[TBL] [Abstract][Full Text] [Related]
20. Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects.
Rivera D; Mejia-Lopez H; Pompa-Mera EN; Villanueva-Mendoza C; Nava-Castañeda A; Garnica-Hayashi L; Cuevas-Covarrubias S; Zenteno JC
Br J Ophthalmol; 2008 Jul; 92(7):998-1002. PubMed ID: 18577654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
